Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685780 | 0.95 | HTR1A (0.50) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL6541577 | 0.89 | CMA1 (0.49) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9684901 | 0.89 | PDE3B (0.51) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9684200 | 0.84 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9684052 | 0.84 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL8114295 | 0.84 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL8786271 | 0.84 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL7762986 | 0.84 | HTR1A (0.45) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9437757 | 0.84 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3AMAPT | |
| SCHEMBL9164783 | 0.83 | HTR1A (0.47) | HTR1AHTR2CPDE3BPDE3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998741-B1 | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | UNILEVER PLC (GB) | 2012-03-07 | — | — | EP | disclosed |
| EP-1998741-A1 | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | UNILEVER PLC (GB) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007112854-A1 | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | UNILEVER PLC (GB) | 2007-10-11 | — | — | WO | disclosed |
| US-20070231282-A1 | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | CONOPCO, INC., D/B/A UNILEVER | 2007-10-04 | — | — | US | disclosed |
| US-7270805-B1 | Skin lightening agents, compositions and methods | CONOPCO, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | PARALLEL WIRELESS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1678170-A1 | USE OF A COMPOUND OF FORMULA (I) AS AN INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (1) THEREAS | Yang Ji Chemical Company Ltd. (KR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005033104-A1 | USE OF A COMPOUND OF FORMULA (I) AS AN INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (1) THEREAS | YANG JI CHEMICAL COMPANY, LTD (KR) | 2005-04-14 | — | — | WO | disclosed |
| US-5240949-A | Analgesics, blood lipid normalizing | ADIR ET COMPAGNIE (FR) | 1993-08-31 | — | — | US | disclosed |
| US-5166353-A | Analgesics, anticholesterol agents, anticoagulants, antilipemic agents | ADIR ET COMPAGNIE (FR) | 1992-11-24 | — | — | US | disclosed |
| US-5162350-A | Analgesics; nontoxic; side effect reduction | ADIR ET COMPAGNIE (FR) | 1992-11-10 | — | — | US | disclosed |
| US-5084469-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1992-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | CYP19A1, CYP17A1, HSD17B11 | HTR1A 2080/4885HTR2C 2840/4885PDE3B 341/4885 |
| US-20070231282-A1 | SKIN LIGHTENING AGENTS, COMPOSITIONS AND METHODS | CUTA, TYR, MCOLN1 | HTR1A 1489/4885HTR2C 1568/4885PDE3B 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.